Search Results - "OLSSON, Anders G"

Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins by Schwartz, Gregory G., MD, PhD, Abt, Markus, PhD, Bao, Weihang, PhD, DeMicco, David, PharmD, Kallend, David, MD, Miller, Michael, MD, Mundl, Hardi, MD, Olsson, Anders G., MD, PhD

“…Abstract Background Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins. It is…”
Get full text

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial by Raal, Frederick J, Prof, Stein, Evan A, Prof, Dufour, Robert, MD, Turner, Traci, MD, Civeira, Fernando, MD, Burgess, Lesley, Prof, Langslet, Gisle, MD, Scott, Russell, Prof, Olsson, Anders G, Prof, Sullivan, David, MD, Hovingh, G Kees, MD, Cariou, Bertrand, MD, Gouni-Berthold, Ioanna, MD, Somaratne, Ransi, MD, Bridges, Ian, MSc, Scott, Rob, MD, Wasserman, Scott M, MD, Gaudet, Daniel, Prof

“…Summary Background Heterozygous familial hypercholesterolaemia is characterised by low cellular uptake of LDL cholesterol, increased plasma LDL cholesterol…”
Get full text

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial by Charytan, David M, Sabatine, Marc S, Pedersen, Terje R, Im, KyungAh, Park, Jeong-Gun, Pineda, Armando Lira, Wasserman, Scott M, Deedwania, Prakash, Olsson, Anders G, Sever, Peter S, Keech, Anthony C, Giugliano, Robert P

“…Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. The purpose of this study was to compare outcomes with evolocumab and placebo according to…”
Get full text

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study by Sjouke, Barbara, MD, Langslet, Gisle, MD, Ceska, Richard, Prof, Nicholls, Stephen J, Prof, Nissen, Steven E, Prof, Öhlander, Maria, MSc, Ladenson, Paul W, Prof, Olsson, Anders G, Prof, Hovingh, G Kees, MD, Kastelein, John J P, Prof

“…Summary Background Eprotirome is a liver-selective thyroid hormone receptor agonist that has been shown to lower plasma LDL cholesterol concentrations in…”
Get full text

Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome by Schwartz, Gregory G., MD, PhD, Olsson, Anders G., MD, PhD, Ballantyne, Christie M., MD, Barter, Phillip J., MD, PhD, Holme, Ingar M., PhD, Kallend, David, MB, BS, Leiter, Lawrence A., MD, Leitersdorf, Eran, MD, McMurray, John J.V., MD, Shah, Prediman K., MD, Tardif, Jean-Claude, MD, Chaitman, Bernard R., MD, Duttlinger-Maddux, Regina, PhD, Mathieson, John, PhD

“…Background Despite contemporary therapies for acute coronary syndrome (ACS), morbidity and mortality remain high. Low levels of high-density lipoprotein (HDL)…”
Get full text

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease by Faergeman, Ole, MD, DMSc, Holme, Ingar, PhD, Fayyad, Rana, PhD, Bhatia, Sonal, MD, Grundy, Scott M., MD, PhD, Kastelein, John J.P., MD, PhD, LaRosa, John C., MD, Larsen, Mogens Lytken, MD, DMSc, Lindahl, Christina, MD, Olsson, Anders G., MD, PhD, Tikkanen, Matti J., MD, PhD, Waters, David D., MD, Pedersen, Terje R., MD, PhD

“…We determined the ability of in-trial measurements of triglycerides (TGs) to predict new cardiovascular events (CVEs) using data from the Incremental Decrease…”
Get full text

Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL Study by Zamani, Payman, Schwartz, Gregory G., Olsson, Anders G., Rifai, Nader, Bao, Weihang, Libby, Peter, Ganz, Peter, Kinlay, Scott

“…Background In acute coronary syndromes, C‐reactive protein (CRP) strongly relates to subsequent death, but surprisingly not to recurrent myocardial infarction…”
Get full text

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to Simvastatin therapy in 4S by BALLANTYNE, Christie M, OLSSON, Anders G, COOK, Thomas J, MERCURI, Michele F, PEDERSEN, Terje R, KJEKSHUS, John

“…Patients with low HDL cholesterol (HDL-C) and elevated triglyceride had an increased risk for coronary heart disease (CHD) events and received the greatest…”
Get full text

Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein by Pitts, Reynaria, MD, Gunzburger, Elise, MS, Ballantyne, Christie M., MD, Barter, Philip J., MD, PhD, Kallend, David, MBBS, Leiter, Lawrence A., MD, Leitersdorf, Eran, MD, McMurray, John J.V., MBChB, Nicholls, Stephen J., MBBS, PhD, Niesor, Eric J., PhD, Olsson, Anders G., MD, PhD, Shah, Prediman K., MD, Tardif, Jean-Claude, MD, Kittelson, John, PhD, Schwartz, Gregory G., MD, PhD

“…The 2 regression lines differ (p < 0.001), with an upward shift and a decreased slope with dalcetrapib. [...]for any given change in HDL-C, the associated…”
Get full text

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials by Willeit, Peter, Ridker, Paul M, Nestel, Paul J, Simes, John, Tonkin, Andrew M, Pedersen, Terje R, Schwartz, Gregory G, Olsson, Anders G, Colhoun, Helen M, Kronenberg, Florian, Drechsler, Christiane, Wanner, Christoph, Mora, Samia, Lesogor, Anastasia, Tsimikas, Sotirios

“…Elevated lipoprotein(a) is a genetic risk factor for cardiovascular disease in general population studies. However, its contribution to risk for cardiovascular…”
Get full text

Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study by Kinlay, Scott, Schwartz, Gregory G, Olsson, Anders G, Rifai, Nader, Szarek, Michael, Waters, David D, Libby, Peter, Ganz, Peter

“…OBJECTIVE—Patients with acute coronary syndromes have an increased risk of stroke. We measured markers of inflammation in the MIRACL study, a randomized trial…”
Get full text

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial by Sullivan, David, Olsson, Anders G, Scott, Rob, Kim, Jae B, Xue, Allen, Gebski, Val, Wasserman, Scott M, Stein, Evan A

“…CONTEXT An estimated 10% to 20% of patients cannot tolerate statins or adequate doses to achieve treatment goals. Plasma proprotein convertase subtilisin/kexin…”
Get full text

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial) by Pedersen, Terje R., MD, PhD, Cater, Nilo B., MD, Faergeman, Ole, MD, DMSc, Kastelein, John J.P., MD, PhD, Olsson, Anders G., MD, PhD, Tikkanen, Matti J., MD, PhD, Holme, Ingar, PhD, Larsen, Mogens Lytken, MD, DMSc, Lindahl, Christina, MD, Szarek, Michael, PhD

“…Previous studies have demonstrated that benefits of intensive statin therapy compared to standard statin therapy begin shortly after an acute event and are…”
Get full text

Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial by Fellström, Bengt, Holdaas, Hallvard, Jardine, Alan G., Holme, Ingar, Nyberg, Gudrun, Fauchald, Per, Grönhagen-Riska, Carola, Madsen, Søren, Neumayer, Hans-Hellmut, Cole, Edward, Maes, Bart, Ambühl, Patrice, Olsson, Anders G., Hartmann, Anders, Logan, John O., Pedersen, Terje R.

“…Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Hyperlipidemia is a risk factor for long-term renal…”
Get full text

Effectiveness and Safety of Laropiprant on Niacin-Induced Flushing by Maccubbin, Darbie L., PhD, Chen, Fabian, MD, PhD, Anderson, Jennifer Weimer, BS, Sirah, Waheeda, BS, McCrary Sisk, Christine, BS, Kher, Uma, PhD, Olsson, Anders G., MD, PhD, Bays, Harold E., MD, Mitchel, Yale B., MD

“…Extended-release niacin (ERN) improves multiple lipid parameters but is underused owing to niacin-induced flushing (NIF). Laropiprant (LRPT) reduces NIF;…”
Get full text

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome by Schwartz, Gregory G, Olsson, Anders G, Abt, Markus, Ballantyne, Christie M, Barter, Philip J, Brumm, Jochen, Chaitman, Bernard R, Holme, Ingar M, Kallend, David, Leiter, Lawrence A, Leitersdorf, Eran, McMurray, John J.V, Mundl, Hardi, Nicholls, Stephen J, Shah, Prediman K, Tardif, Jean-Claude, Wright, R. Scott

“…Dalcetrapib, an inhibitor of cholesteryl ester transfer protein, raises HDL cholesterol levels. In this clinical trial involving patients with an acute…”
Get full text

Effects of High-Dose Atorvastatin in Patients ≥65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study) by Olsson, Anders G., MD, PhD, Schwartz, Gregory G., MD, PhD, Szarek, Michael, MS, Luo, Don, PhD, Jamieson, Michael J., MD

“…After acute coronary syndromes (ACSs), older patients are particularly susceptible to early complications, including death and recurrent ACS. Lipid management…”
Get full text

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) by PEDERSEN, T. R, OLSSON, A. G, MIETTINEN, T, CHRISTOPHERSEN, B, TOBERT, J. A, MUSLINER, T. A, COOK, T. J, FAERGEMAN, O, KJEKSHUS, J, WEDEL, H, BERG, K, WILHELMSEN, L, HAGHFELT, T, THORGEIRSSON, G, PYÖRÄLÄ, K

“…The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 to 310…”
Get full text

Professor Jeremiah Stamler (1919–2022), “Father of Preventive Cardiology” by Gotto, Antonio M., Olsson, Anders G.

Get full text

Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study) by Tikkanen, Matti J., MD, PhD, Holme, Ingar, PhD, Cater, Nilo B., MD, Szarek, Michael, PhD, Faergeman, Ole, MD, DMSc, Kastelein, John J.P., MD, PhD, Olsson, Anders G., MD, PhD, Larsen, Mogens Lytken, MD, DMSc, Lindahl, Christina, MD, Pedersen, Terje R., MD, PhD

“…The efficacy and safety of atorvastatin (80 mg/day) versus simvastatin (20 to 40 mg/day) in older (age ≥65 years) versus younger (<65 years) patients were…”
Get full text